A International Multicenter, Randomized, Double-Blind, Controlled Phase II/III Study to Evaluate the Efficacy and Safety of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.

Start Date10 Sep 2024

Sponsor / Collaborator

Shanghai Yingli Pharmaceutical Co., Ltd.

ChiCTR2400086436 / RecruitingPhase 2IIT

Single-arm, Exploratory Clinical Study of Adebrelimab Combined with Linperlisib and Nab-paclitaxel in Advanced NSCLC Progressed on Prior Immunotherapy

Start Date01 Jul 2024

Sponsor / Collaborator-

100 Clinical Results associated with Linperlisib

100 Translational Medicine associated with Linperlisib

100 Patents (Medical) associated with Linperlisib

Literatures (Medical) associated with Linperlisib

15 Oct 2024·Clinical Cancer Research

A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma

Article

Author: Li, Fei ; Xu, Zusheng ; Huang, Wenyang ; Qiu, Lugui ; Bao, Hanying ; Wu, Tao ; Jin, Jie ; Wang, Zhen ; Yang, Haiyan ; Cen, Hong ; Li, Zhiming ; Xu, Xiaohong ; Zhou, Keshu

AbstractPurpose:Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- and T-cell lymphomas, but as a drug class, these agents have frequently been observed to have tolerability limitations. Next-generation agents that improve the tolerability while maintaining efficacy are desirable.Patients and Methods:A phase Ib clinical study was conducted with the oral PI3K-delta isoform-selective small-molecule inhibitor, linperlisib, in patients with r/r PTCL, and the clinical benefit was explored by the evaluation of safety and efficacy.Results:In this clinical study, 43 patients with r/r PTCL in China were treated with continuous dosing of 80-mg linperlisib once a day. Treatment-related adverse events (AE) were manageable. The most frequently reported grade 3 AE were neutropenia (21%), pneumonia (11.6%), and hypertriglyceridemia (7%). All other AE were either absent or reported in <5% of the patients. Linperlisib treatment for these patients with r/r PTCL, consisting of the major PTCL subtypes, was observed to have a 60.5% overall response rate with 35% complete responses and led to a median duration of response of 11.1 months, median progression-free survival of 11.8 months, and a median overall survival of >38 months (not reached).Conclusions:With the very promising clinical activity against r/r PTCL, the results of this study support the further investigation of linperlisib for the treatment of r/r PTCL.

01 Aug 2023·Heliyon

Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer

Article

Author: Li, Yixin ; Li, Yiwen ; Liu, Linbo ; Lu, Dan ; He, Wen ; Yang, Yu ; Li, Shuhui ; Ni, Xiangdong ; Li, Yingjue ; Zhao, Bochen ; Deng, Yuwei ; Yan, Zhaoqi

PurposeEndocrine resistance hormone receptor-positive (HR+) advanced breast cancer (ABC) is generally insensitive to immunecheckpoint inhibitors (ICIs). This study sought to determine whether PI3Kδ inhibitor could enhance the sensitivity of endocrine resistance HR + advanced BC to ICIs by reducing immune evasion.MethodsPatient-derived HR + ABC xenografts were implanted into immune-humanized NSG mice and subsequently treated with YY20394 (PI3Kδ inhibitor) and camrelizumab. The mice were monitored for tumor progression, biochemical blood indicators, and peripheral blood T-cell subsets. The xenografted tumors were collected at the end of the treatment cycle and subjected to HE staining, immunohistochemistry and protein phosphorylation analysis. Besides, the xenografted tumors were also used to isolate primary breast cancer cells (BCCs) and regulatory T-cells (Tregs), which were subsequently used to evaluate drug sensitivity in vitro.ResultsThe humanized PDX model showed a favorable initial treatment response to camrelizumab combined with YY20394 and manageable toxicity. YY20394 plus camrelizumab showed a strong inhibitory effect on HR + BC in vivo mediated by suppression of Treg activity and an increased proportion of CD8⁺ T cells. Mice bearing tumors treated with YY20394 and camrelizumab had less invasion, mitotic figures, and ki67 expression, while having higher IL-12 expression compared with other groups. Mechanistically, YY20394 only effectively inhibited the PI3K pathway and proliferation activity in Tregs but not in BCCs.ConclusionOur study suggests PI3Kδ inhibitor could the enhance the efficacy of ICIs in HR + BC PDX models by combating immune suppression and provides a feasible approach that may overcome the resistance of ICIs in HR + BC patients.

14 Apr 2023·Clinical Cancer Research

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

Article

Author: Liu, Lihong ; Gu, Xuekui ; Wang, Tingyu ; Cao, Junning ; Wu, Weixin ; Wu, Huijing ; Zhang, Li ; Li, Zengjun ; Cen, Hong ; Li, Fei ; Qiu, Lugui ; Qiu, Lihua ; Li, Dengju ; Yi, Shuhua ; Sun, Xiuhua ; Cai, Zhen ; Zhu, Weiliang ; Jin, Jie ; Zhou, Keshu ; Zhou, Hui ; Fu, Weijun ; Song, Yuqin ; Zhang, Wei ; Bao, Hanying ; Yang, Yu ; Li, Zhifeng ; Su, Hang ; Xu, Zusheng ; Li, Junmin ; Zhang, Zhihui ; Li, Zhiming

AbstractPurpose:To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.Patients and Methods:Histologically confirmed relapsed and/or refractory patients with FL with disease progression after receiving second-line or greater systemic therapy were enrolled. Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred. The primary outcome for the study was the objective response rate (ORR), with secondary outcomes including the duration of response (DOR), progression-free survival (PFS), overall survival (OS), disease control rate, and drug safety profile.Results:Of 114 screened relapsed and/or refractory patients with FL, 84 were enrolled in the full analysis set (FAS). The ORR of the 84 FAS patients was 79.8% [95% confidence interval (CI), 69.6–87.8, 67 patients], with 13 patients (15.5%) achieving a complete response and 54 patients (64.3%) with a partial response. The median DOR was 12.3 months (95% CI, 9.3–15.9). The median PFS was 13.4 months (95% CI, 11.1–16.7). The 12-month OS rate was 91.4% (95% CI, 82.7–95.8) and a median OS not reached by 42 months. The most frequent (>3%) treatment-related adverse events Grade ≥3 were infectious pneumonia (19.0%), neutropenia (15.5%), decreased lymphocyte count (4.8%), decreased leukocyte count (4.8%), increased lipase (3.6%), decreased platelet count (3.6%), hypertriglyceridemia (3.6%), and interstitial lung disease (3.6%).Conclusions:Linperlisib demonstrated compelling clinical activity and manageable tolerability for relapsed and/or refractory patients with FL who had received at least two prior systemic therapies.

News (Medical) associated with Linperlisib

11 Dec 2023

·www.prnewswire.com

Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib in relapsed or refractory peripheral T-cell lymphoma in an oral session at the American Society of Hematology 2023 Annual Meeting

Linperlisib achieved Overall Response Rate of 48% with 30% being Complete Response and manageable safety profile in the r/r PTCL phase 2 study SHANGHAI and SAN FRANCISCO, Dec. 11, 2023 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (" Yingli Pharma"), a biopharmaceutical company focused on developing oral therapies for cancer and metabolic diseases, today announced the pivotal Phase 2 clinical trial results of the investigation of linperlisib in the treatment of patients with relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL). Linperlisib is a phosphoinositide 3-kinase delta (PI3Kδ) oral inhibitor, approved in China for treatment of patients with r/r follicular lymphoma after systemic therapy. "There is a vital need for new therapies to treat highly aggressive cancers such as r/r PTCL where there are very limited treatment options." said Dr. Jun Zhu, Professor, Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China, who was the leading investigator for this pivotal clinical trial. "In addition to the promising efficacy and well manageable safety of linperlisib in r/r PTCL, it is noteworthy that a high proportion of the treated patients were shown to have a complete response, and responses have been seen in all the major PTCL subtypes." "Our approach is to develop novel oral agents that will allow patients to safely administer at home," said Michael Hui, CEO of Yingli Pharma, "We are delighted that the encouraging results of this study support the use of linperlisib in this hard-to-treat disease and are excited to continue developing linperlisib in more indications. The company has applied for linperlisib marketing approval in r/r PTCL in China based on these pivotal study findings." Mr. Hui added, "We look forward to the results of an ongoing open-label multi-center Phase 2 study in the U.S. and Italy in r/r PTCL and r/r CTCL." Safe and effective treatment of r/r PTCL patients The pivotal r/r PTCL Phase 2 clinical trial enrolled 98 patients (pts) from May 2021 to October 2022 at 25 clinical sites in China. The pts had a median of two lines of prior systemic therapies. Sixty-four pts (73%) had refractory disease, 59 pts (67%) had relapsed disease, and 35 pts (40%) had both relapsed and refractory diseases. All patients received linperlisib at 80 mg QD, the RP2D for the drug, with a minimum of 6 months follow-up. The linperlisib-treated patients (Full Analysis Set N = 88) evaluated by Lugano criteria, had a 48% overall response rate, including 30% complete responses and 18% partial responses, as well as a 68% disease control rate. The median Duration of Response was not reached although the 6-month DOR rate was 75%. The median PFS was 5.5 months (95% CI, 3.5, 15.6) and the median OS was 14.2 months (95%CI, 7.9, not reached). Responses were observed across PTCL subtypes. Linperlisib was well tolerated with a differentiated and manageable safety profile, specifically having very low levels of immune-mediated toxicities. In the linperlisib-treated patient safety dataset (N=98) for the pivotal study, the most common hematologic treatment related adverse events (TRAEs) of Grade≥3 were neutropenia (32%), leukocytopenia (10%), Anemia (6%), Thrombocytopenia (5%), and Lymphocytopenia (5%). The most common nonhematologic TRAEs of Grade≥3 were pneumonia (14%) and upper respiratory tract infection (5%). Immune-mediated Grade≥3 TRAEs including elevated ALT, AST, diarrhea, colitis, rash were not reported or were <5%. Nine patients (9.2%) discontinued from the study due to various adverse events. The safety results of this study were consistent with previously reported data in other linperlisib clinical studies. About linperlisib Linperlisib, a next-generation PI3K-selective oral inhibitor, received marketing approval in China in 2022 for treatment of patients with relapsed and/or refractory follicular lymphoma after two or more systemic therapies. Linperlisib also received U.S. FDA Orphan Drug Designations for follicular lymphoma, chronic lymphocytic leukemia, and T cell lymphomas. Linperlisib is under investigation in multiple additional clinical trials as a monotherapy: frontline PTCL, r/r large granular T lymphocytic leukemia, r/r autoimmune hemolytic anemia; and in combination with other agents: in second line follicular lymphoma and marginal zone lymphoma, frontline PTCL, and r/r CTCL. In the U.S. and EU, linperlisib is being developed by 280Bio, Inc (San Francisco, CA., USA), a wholly-owned subsidiary of Yingli Pharma, in a Phase 2 clinical study in r/r T Cell Lymphomas [PTCL and CTCL]. About Yingli Pharma Shanghai Yingli Pharmaceutical Co., Ltd., founded in 2011 and located in the National Biomedical Industry Base of Shanghai Zhangjiang InnoPark, is a clinical-stage biotechnology company developing oral drugs for oncology and metabolic diseases. Yingli Pharma has partnered with Jiangsu Hengrui Pharmaceuticals Co., Ltd., for Greater China commercialization of linperlisib (Intarel®) in r/r follicular lymphoma that is conditionally approved, and other heme indications. Yingli Pharma is currently developing other oral agents in clinical stage from its oncology portfolio, including YL-13027 (TGFR1 inhibitor), YL17231 (pan-RAS inhibitor), YL-15293 (KRASG12C inhibitor), as well as a rich pipeline of additional novel oral agents in oncology. For more information, please see: SOURCE Shanghai Yingli Pharmaceutical Co., Ltd.

Phase 2Clinical ResultOrphan DrugASHDrug Approval

05 Sep 2022

·www.prnewswire.com

Yingli Pharma Announces First Patient Dosed in Phase 2 Trial of Linperlisib for Peripheral T Cell Lymphoma

SAN FRANCISCO, Sept. 3, 2022 /PRNewswire/ -- Yingli Pharma (the "Company" or "Yingli"), a clinical stage biotechnology company developing oral small molecule drugs for cancers with high unmet need, announced today that the first patient has been dosed in a Phase 2 trial evaluating linperlisib, a potent inhibitor of the delta isoform of PI3 kinase (PI3Kδ) in patients with relapsed/refractory peripheral T/NK cell lymphoma (r/r PTCL). This single arm study will evaluate the safety, efficacy and pharmacokinetics of orally administered linperlisib under a strategic collaboration with The University of Texas MD Anderson Cancer Center. Additional trial sites will include medical centers in the United States and Italy. "We are pleased to commence this study of linperlisib in the United States in patients suffering from advanced PTCL," said Michael Hui, MBA, chief executive officer of Yingli. "Linperlisib is a next generation inhibitor of PI3Kδ with enhanced selectivity and potency to offer strong anti-tumor effect while minimizing potential adverse reactions. We are encouraged by the safety and preliminary efficacy data obtained in Phase 1 dose-finding studies in China and look forward to further evaluating linperlisib's potential in this Phase 2 study." "Patients living with advanced PTCL, an aggressive type of lymphoma, face limited treatment options and most do not respond or stop responding to available therapies. Linperlisib may provide a solution for these patients who need an expanded treatment armamentarium, and we're excited to continue studying the drug's potential as we start the Phase 2 study." Linperlisib, a convenient once daily oral drug, is a small molecule inhibitor of PI3Kδ, a validated target in lymphomas due to its critical role in cell proliferation and survival. This Phase 2 (NCT05274997), single arm, open-label trial will evaluate the safety, efficacy and pharmacokinetic properties of linperlisib monotherapy in adult patients with r/r PTCL who have failed at least one prior line of systemic therapy. Enrolled participants will receive linperlisib 80mg once daily orally in a 28-day cycle. The primary outcome is overall response rate to treatment. Secondary outcomes include duration of response, overall survival, progression-free survival, adverse effects and pharmacokinetics parameters. An estimated 97 patients will be enrolled in the study. About Linperlisib Linperlisib (YY-20394) is a highly selective and potent PI3Kδ inhibitor that has shown a favorable safety profile, encouraging anti-tumor activities and promising PK and pharmaceutical properties as an oral once-a-day agent in late-stage clinical development. A Phase 1 clinical trial was completed in 2020 demonstrating linperlisib to be a safe and tolerable agent, and a recommended Phase 2 dose of 80 mg QD was established. Linperlisib was awarded NMPA Breakthrough Therapy status in China, leading to a Phase 2 study in follicular lymphoma (FL) that was completed and submitted in 2021 to China marketing authority for approval. In addition, linperlisib received FDA Orphan Drug Designations for FL, CLL/SLL and T cell lymphoma. Multiple linperlisib clinical trials in FL, PTCL, other lymphomas, solid tumors, combination with gemcitabine/oxaliplatin in r/r DLBC and combination with therapeutic PD1 antibody are underway in China. Preliminary results of single agent linperlisib from a relapsed or recurrent PTCL Phase1b study were reported at ASCO 2021, indicating an overall response rate of 70% with 33% CRs for this difficult to treat and aggressive form of lymphoma. About Yingli Pharma Yingli Pharma is developing oral small molecule drugs with first-in-class or best-in-class potential for cancers with high unmet need. In addition to linperlisib, Yingli's clinical stage portfolio under development in U.S. and China also includes YL-13027, a TGFbeta Receptor 1 small molecule antagonist, currently in Phase 1, and YL-15293, a KRAS G12C inhibitor in Phase 1 studies that are part of a precision medicine program targeting oncogene drivers in cancer. Yingli is advancing several early-stage precision therapy programs leading to IND-enabling studies this year. For more information, visit http://www.yl-pharma.com

CollaborateAntibodyOrphan DrugBreakthrough TherapyFirst in Class

26 May 2022

·www.globenewswire.com

Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors

Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027, an inhibitor of TGFβ signalingSAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- Yingli Pharma US, Inc, (the “Company” or “Yingli”), a clinical stage biotechnology company developing oral small molecule drugs for cancers and other diseases with high unmet need, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating YL-13027, a potent and selective TGFβ receptor 1 (TGFβR1) inhibitor. The dose-finding exploratory trial in patients with advanced solid tumors is being conducted in collaboration with The University of Texas MD Anderson Cancer Center and 4 clinical centers in the U.S. YL-13027 is an oral inhibitor designed to neutralize TGFβ signaling and enhance immunomodulation in the tumor microenvironment by selectively targeting TGFβR1. The Phase 1 study is evaluating the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027. The dose escalation portion of the study will include up to four cohorts of 3-6 patients who will be treated in 28-day cycles with YL-13027, and it will evaluate the safety and tolerability of the drug to determine the recommended Phase 2 dose. A dose expansion phase is planned to further evaluate the safety, tolerability and anti-tumor activity of the TGFβR1 inhibitor at the recommended Phase 2 dose. The study has an estimated enrollment of 54 participants. “The TGFβ pathway represents a promising target for cancer therapeutics. As yet, no therapies have been approved that inhibit TGFβR1 signaling,” said Michael Hui, MBA, chief executive officer of Yingli. “We are delighted to be opening the clinical study in the U.S. and hope to build on the positive preliminary results seen in the ongoing YL-13027 Phase 1 trial in China with promising pharmacokinetics, safety and preliminary evidence of durable antitumor activity. We believe that our drug has potential as a monotherapy or in combination with immunotherapies, and we’re excited to advance this therapy and provide patients with advanced solid tumors a convenient oral treatment option.” The Phase 1 study is part of an ongoing collaborative agreement between Yingli and MD Anderson. About YL-13027 YL-13027 is a potent and selective oral TGFβR1 inhibitor that is rationally designed to neutralize the TGFβ pathway and enhance immunomodulation in the tumor microenvironment. In IND-enabling studies, YL-13027 showed reliable dose-proportionality and pharmacokinetic properties and was safe and tolerable in toxicity studies. Preliminary results of a Phase 1 dose escalation clinical trial demonstrated that YL-13027 is safe, effective and well-tolerated. Yingli Pharma is also launching a Phase 1b/2 study in China exploring the benefits of YL-13027 in combination with a checkpoint inhibitor. About Yingli Pharma US, Inc.Yingli Pharma US, Inc. is developing oral small molecule drugs with first-in-class or best-in-class potential for cancers and other diseases with high unmet need. Its lead clinical candidate, linperlisib, is a next-generation PI3 kinase delta (PI3kδ) inhibitor under review in China for marketing approval in follicular lymphoma. Linperlisib is also under evaluation in a U.S. Phase 2 study in relapsed and refractory peripheral T cell lymphoma. Yingli’s clinical stage portfolio also includes YL-15293, a KRAS G12C inhibitor that is a part of its precision medicine program targeting oncogene drivers in cancer, under development in U.S. and China. In addition, Yingli is advancing several early-stage precision therapy programs leading to IND-enabling studies this year. For more information, visit http://www.yl-pharma.com Yingli Contact:Tes (Marites) Sotto Yingli Pharma US, Inctsotto@yl-pharma.com+1 650-410-5000 Media Contact:Veronica Eames LifeSci Communicationsveames@lifescicomms.com+1 646-970-4682

CollaborateFirst in ClassSmall molecular drug

100 Deals associated with Linperlisib

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Recurrent Follicular Lymphoma	CN	Shanghai Yingli Pharmaceutical Co., Ltd.	08 Nov 2022
Refractory Follicular Lymphoma	CN	Shanghai Yingli Pharmaceutical Co., Ltd.	08 Nov 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Peripheral T-Cell Lymphoma	NDA/BLA	CN	Jiangsu Xuantai Pharmaceutical Co., Ltd	07 Sep 2023
Peripheral T-Cell Lymphoma	NDA/BLA	CN	Shanghai Yingli Pharmaceutical Co., Ltd.	07 Sep 2023
thymic carcinoma	Phase 2	CN	Shanghai Yingli Pharmaceutical Co., Ltd.	28 Jul 2021
NK-cell lymphoma	Phase 2	CN	Shanghai Yingli Pharmaceutical Co., Ltd.	12 Mar 2021
Refractory Follicular Lymphoma	Phase 2	-	Shanghai Yingli Pharmaceutical Co., Ltd.	30 Dec 2020
Diffuse large B-cell lymphoma recurrent	Phase 2	-	Shanghai Yingli Pharmaceutical Co., Ltd.	20 Aug 2020
B-Cell Lymphoma	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Recurrent Indolent Non-Hodgkin Lymphoma	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Refractory Indolent Non-Hodgkin Lymphoma	Phase 2	CN	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	-
Extranodal NK-T-Cell Lymphoma	Preclinical	US	Shanghai Yingli Pharmaceutical Co., Ltd.	01 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Phase 1	B-Cell Malignant Neoplasm	43	Linperlisib	(ewxdvnwurz) = zjdnuylqov oqdpiyplui (jgzrohzdbe, 31.2 - 62.3) View more	-	09 Dec 2023
ASH2023	Phase 2	Extranodal NK-T-Cell Lymphoma	98	Linperlisib 80 mg	wksrfmwxho(nxygswpiue) = dwgqcgxmfy ynwztmdhfz (tychalftpn ) View more	Positive	09 Dec 2023
NCT04370405 (ASH2023)	Phase 2	Refractory Follicular Lymphoma	84	Linperlisib	(wmbbrizjoi) = utncfefjhl nkwuzbigqt (xuhlmcoxdy ) View more	-	09 Dec 2023
NCT04370405 (phase 2 trial, ICML2023)	Phase 2	Follicular Lymphoma	84	Linperlisib 80 mg	(cbodwtmvqc) = rmpjaqizmc rfjfrhvpsf (endkhhtmbv, 64.5 - 86.9) View more	Positive	09 Jun 2023
NCT04370405 (phase 2 trial, ICML2023)	Phase 2	Follicular Lymphoma	84	Placebo	(cbodwtmvqc) = hajvmroatr rfjfrhvpsf (endkhhtmbv, 66.4 - 97.2) View more	Positive	09 Jun 2023
NCT04370405 (EHA2023)	Phase 2	Follicular Lymphoma	84	LINPERLISIB (Relapsed-only disease)	(fbveocppmp) = lzpyovpubw airiauphce (rjxuraqvzw )	-	08 Jun 2023
NCT04370405 (EHA2023)	Phase 2	Follicular Lymphoma	84	LINPERLISIB (Refractory disease)	(fbveocppmp) = ohdbozazul airiauphce (rjxuraqvzw )	-	08 Jun 2023
NCT04370405 (EHA2023)	Phase 2	Follicular Lymphoma	84	Linperlisib 80 mg	(ylvrkwxtjy) = xcobjjzmzp tglzrsmrfk (chlihwehvi, 47.6 - 92.7) View more	-	08 Jun 2023
NCT04500561 (YY-20394-008, EHA2023)	Phase 2	Diffuse large B-cell lymphoma refractory \| Diffuse large B-cell lymphoma recurrent	39	Linperlisib + GEMOX	(iambbbvoar) = sokkbfelmx qnxjozegnj (obhfosmiqb, (40.0 - 97.2)) View more	-	08 Jun 2023
NCT04108325 (ASH2022) Manual	Phase 1	T-cell lymphoma recurrent	43	Linperlisib	(klqckhkllz) = wxskapotbj hhizgsvimk (blxwqxssas ) View more	Positive	15 Nov 2022
EHA2022 Manual	Phase 2	Recurrent Follicular Lymphoma \| Follicular Lymphoma	84	Linperlisib 80 mg	(gmchmwlhux) = owzojwuyoo vblvsczfoc (hejlmywobb, 69.6 - 87.8) View more	Positive	12 May 2022
NCT04370405 (CSCO2021)	Not Applicable	Follicular Lymphoma	93	Linperlisib 80 mg	(qfbpjjyxee) = aizfzhflsz zrdoqnvbiy (duqlyiuxbr ) View more	-	25 Sep 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Linperlisib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation